Acquired resistance remains the most pressing issue: Despite the number of studies published, a complete picture detailing common resistance mechanisms to dual CDK4/6i-ET therapy with clinical validation has yet to be constructed, and prospective, rigorously designed biospecimen collection protocols are needed to acquire pre- and post-treatment tumor samples for further study. The gene discussed is CDK4; the disease is neoplasm.